Compare Medpace Holdings Inc (MEDP) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs ProShares Ultra Gold ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while ProShares Ultra Gold ETF trades at $46.45 (market cap $716.59M). The key difference: Medpace Holdings Inc is far larger — about 23.5× ProShares Ultra Gold ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and ProShares Ultra Gold ETF for 23 Days on average.
| MEDP | UGL | |
|---|---|---|
Market Cap | $16.82B | $716.59M |
Volume | 223,093 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $630.19 | $85.62 |
52-Week Low | $393.42 | $42.79 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
UGL trades at $45.08, up 1.46% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Support is clustered around $44-$45, while resistance sits near $46. Recent news highlights gold's volatility amid shifting Fed rate expectations and Treasury yield pressures, impacting gold-related equities.
The outlook remains cautious due to weak technical momentum and macroeconomic headwinds like rising yields. Upside depends on sustained gold price recovery, but near-term risks from Fed policy and dollar strength suggest limited bullish catalysts. Investors should weigh the stock's sensitivity to commodity cycles against current bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
